WHAT WE DOWe develop more potent clinical leads with fewer side effects at a lower dosage/cost, delivered to non-liver sitesOUR MISSIONAt pacDNA, we aim to transform the field of oligonucleotide therapeutics with safer and more potent drugs that distribute to a wide range of non-liver organs and tissues such as the heart, blood, lung, skeletal muscle, skin, and bone. Our mission is to greatly expand the disease areas where an oligonucleotide-based therapy can be developed, to include major disease categories such as cancer, immunology, metabolic disease, and infectious diseases.Our proprietary delivery technology, termed the Brushield™, boosts the biodistribution in otherwise hard-to-deliver sites, which makes it possible to develop multiple therapies for diseases that are currently out of reach. The technology also promotes tissue retention to up to several months, producing lasting potency. With our technology, there is potential to yield much better treatments, with very low toxicity or side effects from the carrier, increased potency, and smaller, less frequent dosages.